Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 325


Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.

Ascough S, Paterson S, Chiu C.

Front Immunol. 2018 Mar 2;9:323. doi: 10.3389/fimmu.2018.00323. eCollection 2018. Review.


Complete Genome Sequences of 13 Human Respiratory Syncytial Virus Subgroup A Strains of Genotypes NA1 and ON1 Isolated in the Philippines.

Malasao R, Furuse Y, Okamoto M, Dapat C, Saito M, Saito-Obata M, Tamaki R, Segubre-Mercado E, Lupisan S, Oshitani H.

Genome Announc. 2018 Mar 8;6(10). pii: e00151-18. doi: 10.1128/genomeA.00151-18.


Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.

Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, Checchia PA, Carbonell-Estrany X.

Infect Dis Ther. 2018 Mar;7(1):87-120. doi: 10.1007/s40121-018-0188-z. Epub 2018 Feb 22. Review.


Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar.

Abushahin A, Janahi I, Tuffaha A.

Int J Gen Med. 2018 Jan 31;11:41-46. doi: 10.2147/IJGM.S156078. eCollection 2018.


Single-Domain Antibodies As Therapeutics against Human Viral Diseases.

Wu Y, Jiang S, Ying T.

Front Immunol. 2017 Dec 13;8:1802. doi: 10.3389/fimmu.2017.01802. eCollection 2017. Review.


DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections.

Elliott STC, Kallewaard NL, Benjamin E, Wachter-Rosati L, McAuliffe JM, Patel A, Smith TRF, Schultheis K, Park DH, Flingai S, Wise MC, Mendoza J, Ramos S, Broderick KE, Yan J, Humeau LM, Sardesai NY, Muthumani K, Zhu Q, Weiner DB.

NPJ Vaccines. 2017 Jul 6;2:18. doi: 10.1038/s41541-017-0020-x. eCollection 2017.


Enhancing the Thermostability and Immunogenicity of a Respiratory Syncytial Virus (RSV) Live-Attenuated Vaccine by Incorporating Unique RSV Line19F Protein Residues.

Rostad CA, Stobart CC, Todd SO, Molina SA, Lee S, Blanco JCG, Moore ML.

J Virol. 2018 Feb 26;92(6). pii: e01568-17. doi: 10.1128/JVI.01568-17. Print 2018 Mar 15.


Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways in Spain.

Schmidt R, Majer I, García Román N, Rivas Basterra A, Grubb E, Medrano López C.

Health Econ Rev. 2017 Dec 19;7(1):47. doi: 10.1186/s13561-017-0181-3.


Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease.

Cox JA, Hiscox JA, Solomon T, Ooi MH, Ng LFP.

Front Microbiol. 2017 Nov 28;8:2249. doi: 10.3389/fmicb.2017.02249. eCollection 2017. Review.


Chimeric Pneumoviridae fusion proteins as immunogens to induce cross-neutralizing antibody responses.

Olmedillas E, Cano O, Martínez I, Luque D, Terrón MC, McLellan JS, Melero JA, Más V.

EMBO Mol Med. 2018 Feb;10(2):175-187. doi: 10.15252/emmm.201708078.


Association of Age With Risk of Hospitalization for Respiratory Syncytial Virus in Preterm Infants With Chronic Lung Disease.

Winterstein AG, Choi Y, Meissner HC.

JAMA Pediatr. 2018 Feb 1;172(2):154-160. doi: 10.1001/jamapediatrics.2017.3792.


Respiratory syncytial virus seasonality and its implications on prevention strategies.

Janet S, Broad J, Snape MD.

Hum Vaccin Immunother. 2018 Jan 2;14(1):234-244. doi: 10.1080/21645515.2017.1403707. Epub 2017 Dec 15.


Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.


Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants.

Blanken MO, Frederix GW, Nibbelke EE, Koffijberg H, Sanders EAM, Rovers MM, Bont L; Dutch RSV Neonatal Network.

Eur J Pediatr. 2018 Jan;177(1):133-144. doi: 10.1007/s00431-017-3046-1. Epub 2017 Nov 22.


Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants.

Pavilack M, Clifford RA, Gonzales T, Kong AM, Wade S, McLaurin KK.

Infect Dis Ther. 2018 Mar;7(1):121-134. doi: 10.1007/s40121-017-0178-6. Epub 2017 Nov 17.


Association between respiratory syncytial viral disease and the subsequent risk of the first episode of severe asthma in different subgroups of high-risk Australian children: a whole-of-population-based cohort study.

Homaira N, Briggs N, Pardy C, Hanly M, Oei JL, Hilder L, Bajuk B, Lui K, Rawlinson W, Snelling T, Jaffe A.

BMJ Open. 2017 Nov 8;7(11):e017936. doi: 10.1136/bmjopen-2017-017936.


Dynamics of Sendai Virus Spread, Clearance, and Immunotherapeutic Efficacy after Hematopoietic Cell Transplant Imaged Noninvasively in Mice.

Mostafa HH, Vogel P, Srinivasan A, Russell CJ.

J Virol. 2018 Jan 2;92(2). pii: e01705-17. doi: 10.1128/JVI.01705-17. Print 2018 Jan 15.


Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.

Steff AM, Monroe J, Friedrich K, Chandramouli S, Nguyen TL, Tian S, Vandepaer S, Toussaint JF, Carfi A.

Nat Commun. 2017 Oct 20;8(1):1085. doi: 10.1038/s41467-017-01092-4.


Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.

Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X.

BMC Infect Dis. 2017 Oct 17;17(1):687. doi: 10.1186/s12879-017-2803-0.


Steroid resistance and concomitant respiratory infections: A challenging battle in pulmonary clinic.

Dua K, Hansbro NG, Hansbro PM.

EXCLI J. 2017 Jun 29;16:981-985. doi: 10.17179/excli2017-425. eCollection 2017. No abstract available.

Supplemental Content

Support Center